As the CPRD broadly represents the UK population, and SEER-Medicare includes a large, diverse population of older women diagnosed with breast cancer, results are generalisable to women diagnosed with ER/PR+ breast cancer in both the UK, USA and other developed populations due to the homogenous indication of endocrine therapy worldwide. The gene discussed is PGR; the disease is breast carcinoma.